Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

It's not all DAT: harnessing the potential of organic cation transporter 3 inhibition to selectively attenuate amphetamine reinforcement and dopamine release.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Impact of morphine dependence and withdrawal on economic demand for fentanyl, cocaine, and methamphetamine in rats.

Drug and alcohol dependence·2025
Same author

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of psychopharmacology (Oxford, England)·2025
Same author

Naloxone reversal of the cardiorespiratory depressant effects of opioids and mixtures of opioids and stimulants in rats.

Frontiers in pharmacology·2025
Same author

Interactions between cardiorespiratory effects of fentanyl and xylazine and their reversal in male and female Sprague-Dawley rats.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Cardiovascular and locomotor effects of binary mixtures of common 'bath salts' constituents: Studies with methylone, methylenedioxypyrovalerone and caffeine in rats.

British journal of pharmacology·2025
Same journal

Gimmie the Gummies: Initial validation of the Edibles Marijuana Purchase Task.

Experimental and clinical psychopharmacology·2026
Same journal

Feasibility and acceptability of a trauma-informed and peer-supported digital brief intervention for heavy-drinking emerging adults with interpersonal trauma.

Experimental and clinical psychopharmacology·2026
Same journal

App-based contingency management to reduce heavy drinking days among smokers receiving varenicline: Feasibility, acceptability, and efficacy indicators from a phase I analog trial.

Experimental and clinical psychopharmacology·2026
Same journal

Innovations in health behavior research: Current status and strategic future directions.

Experimental and clinical psychopharmacology·2026
Same journal

Cannabis cues, motives, and attention enhancement: A cannabis priming pilot study.

Experimental and clinical psychopharmacology·2026
Same journal

Effects of the neuroactive steroid precursor pregnenolone on stress- and alcohol cue-provoked pain responses in individuals with alcohol use disorder.

Experimental and clinical psychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Narrowing in on compulsions: dopamine receptor functions.

Gregory T Collins1, James H Woods

  • 1Department of Pharmacology, 1301 Medical Science Research Building III, 1150 W. Medical Center Drive, University of Michigan, Ann Arbor, MI 48109-0632, USA. collinsg@umich.edu

Experimental and Clinical Psychopharmacology
|December 18, 2008
PubMed
Summary
This summary is machine-generated.

Dopamine D3/D2 receptors influence compulsive behaviors. Selective D3 agonists may help suppress dopamine-related compulsions, offering new therapeutic avenues.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Area of Science:

  • Neuroscience
  • Pharmacology
  • Behavioral Science

Background:

  • Dopamine receptors, particularly D3 and D2 subtypes, are implicated in reward pathways and motivated behaviors.
  • Compulsive behaviors, often linked to dopamine dysregulation, pose significant challenges in various psychiatric disorders.

Purpose of the Study:

  • To investigate the role of dopamine D3/D2 receptors in compulsive-like behaviors using a rat model.
  • To explore the potential of D3/D2 receptor modulators as therapeutic agents for compulsive disorders.

Main Methods:

  • Administration of D3/D2 receptor agonists and antagonists in rats.
  • Observation and quantification of behaviors such as yawning.
  • Assessment of operant responding in rats with prior cocaine exposure.
  • Evaluation of a selective D3 partial agonist's pharmacological profile.

Main Results:

  • D3 receptor agonists induced yawning, while D2 receptor antagonists inhibited it.
  • Cocaine-experienced rats showed enhanced D3-agonist-induced yawning.
  • Quinpirole (a D3 agonist) promoted persistent responding only when paired with cocaine-associated cues.
  • A novel selective D3 partial agonist demonstrated a unique activity profile.

Conclusions:

  • Dopamine D3 and D2 receptors play distinct roles in mediating and inhibiting compulsive-like behaviors.
  • Enhanced D3 receptor activity may be associated with heightened compulsivity, particularly after drug exposure.
  • Selective D3 receptor modulators, like the partial agonist identified, hold promise for managing dopamine-related compulsions.